Nakanishi Y - Search Results

1

Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer.

Nakanishi Y, Takayama K, Kawasaki M, Yatsunami J, Inutsuka S, Wakamatsu K, Tsuruta N, Hara N. Nakanishi Y, et al. Am J Clin Oncol. 1997 Aug;20(4):393-7. doi: 10.1097/00000421-199708000-00015. Am J Clin Oncol. 1997. PMID: 9256897 Clinical Trial.

2

Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer.

Nakanishi Y, Kawasaki M, Bai F, Takayama K, Pei XH, Takano K, Inoue K, Osaki S, Hara N, Kiyohara C. Nakanishi Y, et al. Oncology. 1999 Nov;57(4):318-23. doi: 10.1159/000012068. Oncology. 1999. PMID: 10575319

3

[Treatment of lung cancer--state of the art in 2000].

Nakanishi Y, Inoue K, Hara N. Nakanishi Y, et al. Gan To Kagaku Ryoho. 2000 Jul;27(8):1247-52. Gan To Kagaku Ryoho. 2000. PMID: 10945023 Review. Japanese.

4

[Lung cancer].

Hara N, Nakanishi Y. Hara N, et al. Among authors: nakanishi y. Nihon Rinsho. 2001 Nov;59 Suppl 7:322-8. Nihon Rinsho. 2001. PMID: 11808138 Review. Japanese. No abstract available.

5

A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.

Harada T, Hamada A, Shimokawa M, Takayama K, Kudoh S, Maeno K, Saeki S, Miyawaki H, Moriyama A, Nakagawa K, Nakanishi Y. Harada T, et al. Among authors: nakanishi y. Jpn J Clin Oncol. 2014 Feb;44(2):127-33. doi: 10.1093/jjco/hyt198. Epub 2013 Dec 29. Jpn J Clin Oncol. 2014. PMID: 24379211 Clinical Trial.

6

P53 immunostaining predicts chemosensitivity in non-small cell lung cancer: A preliminary report.

Kawasaki M, Nakanishi Y, Yatsunami J, Takayama K, Ochiai S, Xinhai P, Kuwano K, Hara N. Kawasaki M, et al. Among authors: nakanishi y. Cancer J Sci Am. 1996 Jul-Aug;2(4):217-20. Cancer J Sci Am. 1996. PMID: 9166535

7

Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer. Fukuoka Lung Cancer Study Group.

Nakanishi Y, Kawarada Y, Hirose N, Ninomiya K, Miyazaki M, Miyazaki N, Kurita Y, Kanegae H, Ohgushi O, Ogata K, Yamazaki H, Inutsuka S, Hara N. Nakanishi Y, et al. Cancer Chemother Pharmacol. 1998;41(6):453-6. doi: 10.1007/s002800050766. Cancer Chemother Pharmacol. 1998. PMID: 9554588 Clinical Trial.

8

Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung.

Yatsunami J, Tsuruta N, Ogata K, Wakamatsu K, Takayama K, Kawasaki M, Nakanishi Y, Hara N, Hayashi S. Yatsunami J, et al. Among authors: nakanishi y. Cancer Lett. 1997 Nov 25;120(1):101-8. doi: 10.1016/s0304-3835(97)00296-6. Cancer Lett. 1997. PMID: 9570392

9

The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.

Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K, Hara N. Kawasaki M, et al. Among authors: nakanishi y. Clin Cancer Res. 1997 Jul;3(7):1195-200. Clin Cancer Res. 1997. PMID: 9815799

10

Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer.

Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C, Hara N. Kawasaki M, et al. Among authors: nakanishi y. Eur J Cancer. 1998 Aug;34(9):1352-7. doi: 10.1016/s0959-8049(98)00067-7. Eur J Cancer. 1998. PMID: 9849416

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,322 results

Search Page

Filters